<DOC>
	<DOCNO>NCT02147444</DOCNO>
	<brief_summary>The efficacy safety novel oral Xa inhibitor stroke systemic embolism , namely rivaroxaban , non-valvular atrial fibrillation patient evaluate Japanese clinical practice .</brief_summary>
	<brief_title>Evaluation Effectiveness Safety Xa Inhibitor Prevention Stroke And Systemic Embolism Nationwide Cohort Japanese Patients Diagnosed Non-valvular Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Patients meet criterion Patients age 20 year Patients diagnose nonvalvular atrial fibrillation Patients treat treated rivaroxaban Patients write informed consent obtain Patients meet criterion The following patient rivaroxaban contraindicate use Patients history allergy ingredient contain drug Patients hemorrhagic event ( intracranial hemorrhage , gastrointestinal hemorrhage clinically significant hemorrhagic event ) Patients liver disease complicate coagulation disorder moderate bad liver disorder ( Grade B C accordance ChildPugh classification ) Patients renal failure ( creatinine clearance : &lt; 15 mL/min ) Women likely pregnant Patients treat HIV protease inhibitor ( include ritonavir , atazanavir indinavir ) Patients treated oral injectable formulation azole antifungal drug ( include itraconazole , voriconazole ketoconazole ( exclude fluconazole ) )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Rivaroxaban</keyword>
	<keyword>Non-valvular atrial fibrillation</keyword>
	<keyword>NOAC</keyword>
	<keyword>Xa inhibitor</keyword>
</DOC>